Arbutus Biopharma Corp
Geschlossen
4.31 2.62
Übersicht
Veränderung der Aktienkurses
24h
Min
4.3
Max
4.32
Einkommen | 4M -3.8M |
|---|---|
Verkäufe | 522K 1.1M |
EPS | -0.014 |
Gewinnspanne | -357.374 |
Angestellte | 19 |
EBITDA | 75K -7.6M |
Nächstes Ergebnis | 13. Mai 2026 |
|---|
Marktkapitalisierung | 4.4M 843M |
|---|---|
Vorheriger Eröffnungskurs | 1.69 |
Vorheriger Schlusskurs | 4.31 |
Technischer Score
By Trading Central
Vertrauen
Weak Bearish Evidence
Arbutus Biopharma Corp Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Arbutus Biopharma Corp Prognose
Finanzen
Vertriebs- und Verwaltungskosten
Betriebsaufwand
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
EBITDA
Betriebsergebnis
$
Über Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
